Ryohei Shibata, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiolitis | 6 | 2024 | 481 | 1.970 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2023 | 149 | 1.650 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2024 | 364 | 1.560 |
Why?
|
| Milk Hypersensitivity | 1 | 2023 | 78 | 0.830 |
Why?
|
| Viruses | 2 | 2023 | 376 | 0.830 |
Why?
|
| Saliva | 1 | 2024 | 820 | 0.690 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 1007 | 0.550 |
Why?
|
| Asthma | 3 | 2023 | 6172 | 0.510 |
Why?
|
| Rhinovirus | 3 | 2023 | 202 | 0.440 |
Why?
|
| Immunoglobulin E | 3 | 2023 | 1484 | 0.410 |
Why?
|
| Caseins | 1 | 2023 | 103 | 0.220 |
Why?
|
| Lithiasis | 1 | 2022 | 19 | 0.210 |
Why?
|
| Choledochal Cyst | 1 | 2022 | 25 | 0.210 |
Why?
|
| Infant | 9 | 2024 | 36060 | 0.210 |
Why?
|
| Splenic Diseases | 1 | 2022 | 90 | 0.190 |
Why?
|
| Cholangitis | 1 | 2022 | 113 | 0.190 |
Why?
|
| Behcet Syndrome | 1 | 2022 | 86 | 0.190 |
Why?
|
| Milk | 1 | 2023 | 443 | 0.180 |
Why?
|
| Hypospadias | 1 | 2021 | 98 | 0.180 |
Why?
|
| Colitis, Ulcerative | 2 | 2024 | 1919 | 0.170 |
Why?
|
| Cholestasis | 1 | 2022 | 377 | 0.170 |
Why?
|
| Anal Canal | 1 | 2022 | 372 | 0.160 |
Why?
|
| Blood Component Removal | 1 | 2020 | 132 | 0.160 |
Why?
|
| Antibodies, Bacterial | 1 | 2024 | 1468 | 0.160 |
Why?
|
| Granulocytes | 1 | 2020 | 551 | 0.150 |
Why?
|
| Cattle | 1 | 2023 | 3847 | 0.150 |
Why?
|
| Intestinal Diseases | 1 | 2022 | 506 | 0.150 |
Why?
|
| Embryonic Development | 1 | 2022 | 716 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 15840 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2022 | 1302 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2024 | 54303 | 0.110 |
Why?
|
| Recurrence | 1 | 2024 | 8482 | 0.100 |
Why?
|
| Monocytes | 1 | 2020 | 2575 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2024 | 3790 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2011 | 535 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2023 | 4642 | 0.070 |
Why?
|
| Humans | 15 | 2024 | 760621 | 0.070 |
Why?
|
| Phenotype | 1 | 2023 | 16546 | 0.060 |
Why?
|
| Child | 5 | 2024 | 79806 | 0.060 |
Why?
|
| Bronchiolitis, Viral | 1 | 2024 | 82 | 0.060 |
Why?
|
| Hospitalization | 1 | 2023 | 10790 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2011 | 1252 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 100 | 0.050 |
Why?
|
| Propionates | 1 | 2023 | 182 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2448 | 0.050 |
Why?
|
| Cloaca | 1 | 2022 | 52 | 0.050 |
Why?
|
| Female | 7 | 2024 | 391270 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 2864 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2024 | 590 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2023 | 41335 | 0.050 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2021 | 80 | 0.050 |
Why?
|
| Splenectomy | 1 | 2022 | 391 | 0.050 |
Why?
|
| Male | 5 | 2024 | 359744 | 0.040 |
Why?
|
| Learning Curve | 1 | 2021 | 231 | 0.040 |
Why?
|
| Urethra | 1 | 2021 | 406 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2011 | 3016 | 0.040 |
Why?
|
| Abscess | 1 | 2022 | 605 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2022 | 1975 | 0.040 |
Why?
|
| Metabolome | 1 | 2024 | 982 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 167963 | 0.030 |
Why?
|
| Needles | 1 | 2020 | 451 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2024 | 15697 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 1791 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2022 | 1063 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2023 | 1804 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 74359 | 0.030 |
Why?
|
| Metabolomics | 1 | 2024 | 1628 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2011 | 10446 | 0.030 |
Why?
|
| Fever | 1 | 2022 | 1617 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2024 | 26181 | 0.030 |
Why?
|
| Intestines | 1 | 2023 | 1907 | 0.030 |
Why?
|
| Lipids | 1 | 2023 | 3336 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2024 | 3047 | 0.030 |
Why?
|
| Aged | 1 | 2024 | 169152 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2011 | 239 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2024 | 65017 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2024 | 42063 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 220352 | 0.020 |
Why?
|
| Adult | 1 | 2024 | 219994 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 613 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2024 | 12766 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2024 | 80372 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 9411 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2022 | 14372 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1672 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 81208 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7408 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5039 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2024 | 23376 | 0.010 |
Why?
|
| Pregnancy | 1 | 2022 | 29749 | 0.010 |
Why?
|
| Adolescent | 1 | 2024 | 87810 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16939 | 0.010 |
Why?
|